Search results
Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 4 days agoBefore we dive into how investors and analysts have reacted as of late, let's take a quick look at...
Analyst firm maintains Outperform on 4D Molecular Therapeutics By Investing.com
Investing.com· 2 days agoThe commentary from BMO Capital addressed investor queries about whether the 1E15vg dose of 4D-710...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 days agoEarnings rocketed 56% to $4.76 per share, on an adjusted basis. Both measures beat Wall Street's...
What's Going On With Arcturus Therapeutics Stock On Friday? - Arcturus Therapeutics (NASDAQ:ARCT)
Benzinga· 2 days agoArcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA...
Arcturus reports positive ARCT-032 cystic fibrosis data By Investing.com
Investing.com· 2 days agoArcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a biotechnology company...
These Are The 5 Best Stocks To Buy And Watch Now
Investor's Business Daily· 6 days agoIn addition, Vertex is working on a next-generation cystic fibrosis treatment, known as vanzacaftor. Vertex's Trikafta is already in use for most...
Belpointe Asset Management LLC Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
ETF DAILY NEWS· 1 day agoBelpointe Asset Management LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 7.4% during the fourth quarter, Holdings Channel reports. The ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Raised by California State Teachers...
ETF DAILY NEWS· 6 days agoCalifornia State Teachers Retirement System lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 1.4% in the 4th quarter, according to the company in its ...
This Is What Whales Are Betting On Vertex Pharmaceuticals - Vertex Pharmaceuticals (NASDAQ:VRTX)
Benzinga· 6 days agoIts key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified ...